Citius Oncology (CTOR) Long-Term Deferred Tax (2023 - 2024)
Citius Oncology's (CTOR) quarterly Long-Term Deferred Tax came in at $7.5 million in Q3 2024, up 62.07% year-over-year from $4.6 million in Q4 2023, and up 62.07% quarter-over-quarter from $4.6 million in Q3 2023.
Powered by 
Analysis
Citius Oncology (CTOR) Long-Term Deferred Tax (2023 - 2024) Analysis & Trends
Citius Oncology (CTOR) has reported Long-Term Deferred Tax for 2 consecutive years, with $7.5 million the latest figure, recorded in Q3 2024.
- On a quarterly basis, Long-Term Deferred Tax rose 62.07% year-over-year to $7.5 million in Q3 2024; TTM through Sep 2024 was $7.5 million, a 62.07% increase from a year earlier, with the FY2024 full-year figure at $7.5 million, up 62.07% from the prior year.
- Long-Term Deferred Tax was $7.5 million for Q3 2024 at Citius Oncology, up from $4.6 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $7.5 million in Q3 2024 and troughed at $4.6 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Citius Oncology | 101.41 Mn | 101.41 Mn | 1.00 Mn |